Antony Koblish, CEO, emphasized the company's continued execution on expanding its commercial footprint, improving operating discipline, and strengthening its patient-centric culture. TELA Bio ...

Moss reiterated, "We expect to have the manuscript and the peer-reviewed publication filed on the MINDFuL trial sometime this month...We expect to have the end of Phase II meeting with the FDA to take ...

Management expects growth momentum to slow to low-single digits in Q4 due to uncertainties around NIH funding and tariffs. Adjusted operating margin is projected to be 100 to 150 basis points lower in ...

– Company plans to meet with the FDA to align on registrational trial designs in 1H25 based on emerging clinical profile of resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and ...

Earnings Call Insights: Bio-Rad Laboratories, Inc. (BIO) Q3 2025 Jonathan DiVincenzo, President & COO, reported that "revenue was consistent with our outlook and operating margin exceeded consensus, a ...

Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...

Bio-Path (BPTH) outlined the growing body of scientific evidence that Bio-Path believes supports the development of BP1001-A for the treatment for obesity and related metabolic diseases in Type 2 ...

Rachel King is a trailblazer in biotech, a venture capitalist turned co-founder and CEO, now turned industry leader. As CEO of the Biotechnology Innovation Organization (BIO), King has focused in ...